- Home
- NKSH vs RCEL Comparison
NKSH vs RCEL Comparison
Compare NKSH & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKSH
- RCEL
- Stock Information
- Founded
- NKSH 1891
- RCEL N/A
- Country
- NKSH United States
- RCEL United States
- Employees
- NKSH N/A
- RCEL N/A
- Industry
- NKSH Major Banks
- RCEL Medical/Dental Instruments
- Sector
- NKSH Finance
- RCEL Health Care
- Exchange
- NKSH Nasdaq
- RCEL Nasdaq
- Market Cap
- NKSH 163.0M
- RCEL 161.5M
- IPO Year
- NKSH N/A
- RCEL N/A
- Fundamental
- Price
- NKSH $25.29
- RCEL $5.19
- Analyst Decision
- NKSH Strong Buy
- RCEL Strong Buy
- Analyst Count
- NKSH 1
- RCEL 4
- Target Price
- NKSH $38.00
- RCEL $16.50
- AVG Volume (30 Days)
- NKSH 17.7K
- RCEL 293.0K
- Earning Date
- NKSH 08-13-2025
- RCEL 08-07-2025
- Dividend Yield
- NKSH 5.97%
- RCEL N/A
- EPS Growth
- NKSH N/A
- RCEL N/A
- EPS
- NKSH 1.38
- RCEL N/A
- Revenue
- NKSH $46,211,000.00
- RCEL $71,661,000.00
- Revenue This Year
- NKSH N/A
- RCEL $57.29
- Revenue Next Year
- NKSH $5.93
- RCEL $28.07
- P/E Ratio
- NKSH $18.28
- RCEL N/A
- Revenue Growth
- NKSH 2.21
- RCEL 41.35
- 52 Week Low
- NKSH $23.75
- RCEL $5.10
- 52 Week High
- NKSH $33.37
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- NKSH 41.57
- RCEL 29.07
- Support Level
- NKSH $25.32
- RCEL $5.10
- Resistance Level
- NKSH $27.75
- RCEL $6.33
- Average True Range (ATR)
- NKSH 0.77
- RCEL 0.32
- MACD
- NKSH -0.10
- RCEL 0.02
- Stochastic Oscillator
- NKSH 18.27
- RCEL 6.10
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.